Second-line antiretroviral treatment successfully resuppresses drug-resistant hiv-1 after first-line failure: Prospective cohort in sub-saharan africa

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1739-1744

  Sigaloff, Kim C E ^a   Hamers, Raph L ^a   Wallis, Carole L ^b   Kityo, Cissy ^c   Siwale, Margaret ^d   Ive, Prudence ^b   Botes, Mariette E ^e   Mandaliya, Kishor ^f   Wellington, Maureen ^g   Osibogun, Akin ^h   Stevens, Wendy S ^b   Van Vugt, Michle ^a   Rinke De Wit, Tobias F ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d Lusaka Trust Hospital   (Zambia)

^e Muelmed Hospital   (South Africa)

^f Department of Obstetrics and Gynaecology   (Kenya)

^g Newlands Clinic   (Zimbabwe)

^h LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SECOND LINE ANTIRETROVIRAL TREATMENT; VIRUS INHIBITION; VIRUS MUTATION;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROSPECTIVE STUDIES; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84861080144     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis261     Document Type: Article

References (15)

1. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22:1305-12.
2. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48: 115-22.
3. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
4. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: highlevel nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127-34.
5. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-8.
6. Hamers RL, Oyomopito R, Kityo C, et al. Cohort Profile: The Pharm Access African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2011. Epub ahead of print.
7. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach, 2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 21 April 2011.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-63.
9. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18.
10. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving secondline HIV therapy in resource-limited countries. JAMA 2010; 304: 303-12.
11. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500-6.
12. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46. (Pubitemid 34680595)
13. Bartlett JA, Aga E, Ribaudo H, et al. A Pilot Study of LPV/r Monotherapy following Virologic Failure of First-line NNRTI-containing Regimens in Resource-limited Settings: The Week-24 Primary Analysis of ACTG 5230 [abstract 583]. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA: 2011.
14. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-91.
15. Bunupuradah T, Chetchotisakd P, Munsakul W, et al. Second-line LPV/r Monotherapy Was Inferior to TDF/3TC/LPV/r in Patients who Failed NNRTI Regimen: HIV STAR Study [abstract 584]. In: Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA: 2011.